Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7337 Injection Rate Finding in Liver CT
NCT00165620Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2004
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iomeprol in liver disease and Liver lesion, sponsored by Eisai Co., Ltd. Primary endpoints: Contrast enhancement effect in the early arterial phase and Warming sensation and vascular pain. Started Nov 2004; status: completed.
02
Drugs
iomeprol
03
Conditions
liver diseaseLiver lesion
Beyond the preview
Go deeper on NCT00165620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165620.